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Abstract: HIV-infected patients show high risk of fracture. The aims of our study were to determine
the prevalence of vertebral fractures (VFs) and their associations with vitamin D in HIV patients. 100
patients with HIV infection and 100 healthy age- and sex-matched controls were studied. Bone mineral
density was measured by quantitative ultrasound at the non-dominant heel. Serum osteocalcin
and C-terminal telopeptide of collagen type 1 served as bone turnover markers. Bone ultrasound
measurements were significantly lower in patients compared with controls (Stiffness Index (SI):
80.58 ± 19.95% vs. 93.80 ± 7.10%, respectively, p < 0.001). VFs were found in 16 patients and in 2
controls. HIV patients with vertebral fractures showed lower stiffness index (SI) (70.75 ± 10.63 vs.
83.36 ± 16.19, respectively, p = 0.045) and lower vitamin D levels (16.20 ± 5.62 vs. 28.14 ± 11.94,
respectively, p < 0.02). The majority of VFs (87.5%) were observed in HIV-infected patients with
vitamin D insufficiency, and regression analysis showed that vitamin D insufficiency was significantly
associated with vertebral fractures (OR 9.15; 95% CI 0.18–0.52, p < 0.04). VFs and are a frequent
occurrence in HIV-infected patients and may be associated with vitamin D insufficiency.
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1. Introduction
Low bone mineral density (BMD) is a common finding in HIV-infected patients [1,2], and a
higher prevalence of osteopenia and osteoporosis up to 70% and 30%, respectively, was reported [3,4].
A systematic review concluded that the probability of osteopenia and osteoporosis could be over
6-fold and almost 4-fold higher in HIV-infected than in the non-infected population, respectively [5],
and low BMD is associated with increased risk of bone fragility fractures. HIV-infected patients have
been reported to show a higher rate of fragility fractures with an almost 9-fold increased risk of hip
fracture and 3-fold increased risk of overall fractures [6–8]. Multiple factors appear to be involved
in the pathogenesis of bone loss in HIV-infected patients, including HIV viral protein, antiretroviral
therapy (ART) side effects, inflammatory cytokines, and bone turnover in addition to traditional risk
factors [9–15]. As is known, vitamin D plays a prominent role in bone and mineral metabolism, and it
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has been suggested to be involved in the pathogenesis of decreased bone mass and fractures in the
general population [16]; thus, it is plausible that vitamin D may exert a role in bone loss and fragility
fractures also in HIV-infected patients. The aims of our study were to determine the prevalence of
vertebral fractures and to assess the role of bone ultrasound parameters, bone turnover markers, and
vitamin D in relation to vertebral fractures in HIV-infected patients.
2. Results
Demographic and clinical features of participants are shown in Table 1. As expected in light of
the matching design of the study, chronological age (p = 0.73) and sex (p = 1.00) and family history
of osteoporosis and fracture (p = 0.79) were comparable in HIV-infected patients and controls. Other
relevant factors associated with BMD were also non-significantly different in the two groups (Table 1).
The ultrasound parameter at calcaneus, SI was significantly lower in HIV-infected patients in comparison
with control (SI: 80.58 ± 19.95% vs. 93.80 ± 7.10%, p < 0.001) (Figure 1a). Serum levels of calcium and
phosphorus, urinary calcium and phosphorus (Figure 2a–d), and bone turnover markers (Figure 3c,d) did
not differ significantly between the study groups. The level of PTH was higher, albeit not significantly,
in patients compared with control subjects (Figure 3a). 25-Hydroxivitamin D3 (25(OH)D3) level was
significant lower (20.29 ± 4.05 ng/mL vs. 35.77 ± 6.50 ng/mL, p < 0.001) in HIV-infected patients
compared with controls (Figure 3b). Lateral spine X-ray documented single or multiple VFs in 16 patients
(16%) and 2 controls, with a significantly different prevalence in the two groups (p < 0.05). Ten patients had
a single Grade-1 fracture, 5 patients had two Grade-3 fractures, and 1 patient had multiple fractures (two
Grade-1 and three Grade-3). In HIV-infected patients, the comparison between subjects without vertebral
fractures (No-VFs) and subjects with VFs showed that this latter group reported a poorer measurement of
SI (83.36± 16.19 vs. 70.75± 10.63; p = 0.045) (Table 2) and a lower 25(OH)D3 (28.14± 11.94 vs. 16.2± 5.62;
p < 0.02) (Table 2). No statistically significant differences were found in age, BMI, smoking habits, and
viro-immunological markers between fractured and non-fractured patients.
VFs were significantly associated with the insufficiency of 25(OH)D3, and these associations were
significant after adjusting for age, renal function, and systemic hypertension. No other significant
associations were found between 25(OH)D3 serum levels and the other clinical parameters assessed in
HIV-infected patients.
Table 1. Anthropometric data and risk factors for fractures in two groups; results are expressed as
number, means ± S.D., and percentage.
Characteristics HIV (n = 100) Controls (n = 100) p
Age (years) 45.36 ± 12.02 44.85 ± 9.30 0.73
Body Mass Index (kg/m2) 25.01 ± 4.23 24.80 ± 4.65 0.73
Sex (F/M) 84/16 84/16 1.00
Duration of disease (years) 16.29 ± 6.48 0 N/A
Current tobacco use, n (%) 22 (22) 20 (20) 0.88
Alcohol intake (mL/week) 450 ± 100 450 ± 80 1.00
Calcium intake (mg/day) 510 ± 117.88 520 ± 122.53 0.55
Food energy (Kcal/day) 1350 ± 200 1360 ± 150 0.23
Low physical activity 70 68 0.66
Supplementation with calcium, n 0 0 N/A
Supplementation with vitamin D, n 0 0 N/A
Current steroid use, n (%) 0 0 N/A
Antiretroviral therapy exposure
Naive, n (%) 6 (6) 0 N/A
Experienced, n (%) 94 (94) 0 N/A
Sunlight exposure >5 h/week, n (%) 26 (26) 26 (26) 0.52
Family history of osteoporosis
and/or fractures, n (%) 12 (12) 14 (14) 0.79
Fall history, n (%) 15 (15) 17 (17) 0.87
N/A: not applicable.
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Table 2. Bone ultrasound parameter, laboratory data, and vertebral fractures in HIV infection and
control group; results are expressed as number, means ± S.D. and percentage.
Parameter HIV (n = 100) Control Group (n = 100)
Vertebral fractures (VFs), n (%) 16 (16) * 2 (2)
Stiffness index (SI) (%) 80.58 ± 19.95 § 92.18 ± 8.06
T-Score (D.S.) −1.70 ± 0.50 § -0.70 ± 0.30
Z-Score (D.S.) −1.20 ± 0.40 § -0.10 ± 0.30
Osteocalcin (pg/mL) 21.31 ± 4.95 20.33 ± 4.35
C-terminal telopeptide (ng/mL) 0.53 ± 0.28 0.48 ± 0.35
Parathyroid hormone level (pg/dL) 43.72 ± 25.40 37.64 ± 23.60
25-hydroxivitamin D3 (ng/mL) 20.29 ± 4.05 § 35.77 ± 6.50
Calcium (mg/dL) 9.02 ± 0.47 9.12 ± 0.46
Phophate (mg/dL) 3.11 ± 0.57 3.14 ± 0.43
Urinary calcium (mg/24 h) 210.29 ± 84.05 213.93 ± 140.35
Urinary phophate (mg/24 h) 1010.29 ± 260.05 1063.53 ± 461.50
Vitamin A (g/dL) 62.65 ± 13.89 62.33 ± 13.22
Creatinine (mg/dL) 0.88 ± 0.07 0.89 ± 0.09
* p < 0.05; § p < 0.001.
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Figure 1. Bone Ultrasound parameters and related T and Z-score in HIV infected (HIV) and control 
group (Ctrl). * p < 0.001. Data are expressed as means and SD. (a) The baseline differences of stuffness 
index between HIV group (HIV) and control group (Ctrl) at 0, was statistically significant; (b) The 
baseline differences of T-score between HIV group and control group (Ctrl) at 0, was statistically 
significant; (c) The baseline differences of Z-score between HIV group and control group (Ctrl) at 0, 
was statistically significant. 
Figure 1. Bone Ultrasound parameters and related T and Z-score in HIV infected (HIV) and c ntrol
group (Ctrl). * p < 0.001. Data are expres ed as means and SD. (a) Th baselin differences of stuffness
index b tween HIV group (HIV) and cont l group (Ctrl) at 0, w s atistically s gnificant; (b) The
baseline differences of T-score b tween HIV group and c nt l group (Ctrl) at 0, w s tatistically
s gnificant; (c) The baseline differences of Z-score b tween HIV group and cont l group (C rl) at 0,
w s atistically s gnificant.
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Figure 3. Serum parathyroid hormone (PTH), 25(OH)D3 and bone turnover markers in two groups.
* p < 0.001. Data are expressed as means and SD. (a) The baseline differences of serum parathyroid
hormone between HIV group (HIV) and control group (Ctrl) was not statistically significant (p = 0.08);
(b) The baseline differe ces of Serum 25-OH-D3 between HIV group (HIV) and control group (Ctrl) was
not statistically significant (p = 0.0001); (c The baseline differences of osteocalcin betwe n HIV group
(HIV) and control group (Ctrl) was not statistically significant (p = 0.13); (d) The baseline differences of
CTx between HIV group (HIV) and control group (Ctrl) was not statistically significant (p = 0.26).
Int. J. Mol. Sci. 2018, 19, 119 5 of 9
3. Discussion
Our data show that HIV-infected patients exhibited lower BMD as assessed by bone quantitative
ultrasound at the heel. SI measurements and the related T- and Z-score values were significantly lower
in the HIV-infected patients compared with the control group, the latter being matched with patients
not only for sex and age but also for other known major risk factors for osteoporosis and fractures.
The X-ray of the thoracic and lumbar spine showed single or multiple VFs, according to the
Genant semiquantitative classification of VFs, in 16 HIV-infected patients with a prevalence of 16%
and in only two subjects from the control group. These data are consistent with the current literature
and highlight the high risk of fracture in this cohort [17–19]. Age, chronic renal insufficiency, and
steroid use were previously associated with increased risk of fractures in HIV-infected patients [20,21].
However, since there are no significant differences between our HIV-infected patients and the controls,
when considering these variables, it is reasonable to rule out that a low BMD and VFs are related to
these factors.
Another important determinant of bone loss and fragility fractures in HIV-infected patients is
represented by ART, in fact several studies, but not all, have proved the association between ART
exposure and osteoporosis and/or fractures [22–24].
In our study, 94% of HIV-infected patients were treated with ART, so it was not possible to analyze
the impact of the therapy, per se, on BMD and fractures. Interestingly, the HIV-infected patients
with VFs reported a lower value of SI in comparison with HIV-infected patients without VFs; this
result is consistent with previous data on the role of quantitative ultrasound in the detection of bone
fragility. Quantitative ultrasound is able to reflect different physical properties of bone (e.g., the density,
elasticity, and microarchitecture) and provide information on fracture risk [25–30].
Our data may indicate that bone ultrasound at the non-dominant heel may be used as a reliable
tool to test bone health in HIV-infected patients.
Great attention has been given to the field of vitamin D in HIV-infected patients over the
last few years, and epidemiological data suggest that HIV-infected patients, also from different
geographical locations, including Europe, American, and Australia have a high prevalence of vitamin
D insufficiency [31–33]. In our cohort, the prevalence of insufficiency of vitamin D3 in HIV-infected
patients was 50%, significantly higher compared to the control group (20%). Diet and exposure
to the sun are the main factors that regulate vitamin D3 levels and its activity in each subject [34].
The average self-reported sun exposure was the same in both groups, so sun exposure is not likely to
be the cause of the low 25(OH)D3 level showed in HIV group than controls. Poor vitamin D status
is a well-established risk factor for bone disease in the general population [35]. In addition, recent
data suggest that vitamin D may exert non-skeletal functions, having a role in cardiovascular and
immune regulation [36–38]. Moreover, in HIV human macrophages exposed to mycobacterium
tuberculosis, vitamin D pretreatment restored critical responses, supporting a potential role for
exogenous vitamin D as a therapeutic adjuvant in M. tuberculosis infection in HIV(+) persons [39].
The extent to which vitamin D deficiency contributes to bone loss and enhance fracture risk in the
HIV-infected patients is largely unknown. Our study demonstrated that vitamin D insufficiency is
associated with prevalent vertebral fractures in HIV-infected patients: 87.5% of HIV-infected patients
presenting VFs had serum with a vitamin D value lower than 30 ng/mL, and vitamin D was predictive
of fractures according to regression analysis. The finding that insufficient 25-hydroxyvitamin D3 levels
(<30 ng/mL) are associated with VFs support the clinical relevance of vitamin D preserving bone
health also in HIV-infected patients, and supports the inclusion of this modifiable risk factor as part of
the screening for bone fragility in HIV-infected patients.
We acknowledge that our study has some limitations, including the small sample size and its
cross-sectional and observational nature, that need to be considered when interpreting the final results.
Another limitation was not to compare the population of HIV with another chronic disease to better
understand the impact and specificity of HIV on bone loss and vertebral fragility fractures.
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4. Materials and Methods
4.1. Subjects
The study was approved by the Local Ethics Committee for Medical Research, Messina University
Hospital “G.Martino” and carried out in accordance with the Helsinki Declaration. All subjects gave
their informed written consent to enter the study. One hundred consecutive patients with diagnosis
of HIV infection referred from July 2012 to February 2015 to the Infection Unit of the University
Hospital of Messina were evaluated. Eligibility criteria required the absence of clinical or laboratory
abnormalities that suggested cardiovascular, hepatic, or renal disorders; coagulopathy, the use of
oral or transdermal estrogen, progestin, androgen, or other steroids; previous or current use of
bone active agents (e.g., biphosphonates), the use of cholesterol-lowering therapy, cardiovascular
medications, or any other therapy that could influence bone metabolism, in particular, systemic or
local corticosteroids. Of the 141 patients evaluated, 100 fulfill the inclusion criteria and were included
in this cross-sectional study. One hundred healthy volunteers matched for sex and age served as the
control group. All participants in both groups were white subjects from South Italy. Clinical data,
including smoking status (current, former, never), physical activity, food energy, calcium intake, and
sun exposure, were obtained by interview, and weight and height were determined during physical
examination. The nutritional variables were determined using 24 h recall. None of the subjects in
either group were on supplementation with calcium and/or vitamin D.
4.2. Bone Ultrasound Parameters and Vertebral Fractures Assessment
All subjects underwent a BMD evaluation by quantitative ultrasound (QUS) at the non-dominant
heel by Achilles Insight, (Lunar, Madison, WI, USA). The Achilles Plus measures the speed
of sound (SOS), broadband ultrasound attenuation (BUA), and a clinical index called stiffness
index. Stiffness index (SI) is calculated automatically by the software according to the following
formula: SI = (0.67 × BUA + 0.28 × SOS) − 420. Standardized procedures were carried out for patient
positioning, data acquisition, and system calibrations. The manufacturer’s phantom was used for
system calibrations. The coefficient of variation for SI was 1.7%.
All participants also underwent a lateral thoracic and lumbar spine X-ray to ascertain the
presence of VFs. All radiographs were assessed by two blinded physicians separately according
to the quantitative methods (quantitative vertebral morphometry, QVM) using a dedicated software
(MorphoXpress). Anterior, middle, and posterior heights of vertebral T4 to L4 were measured.
According to the Genant classification, a vertebral fracture was defined based on reduction in anterior,
middle, and/or posterior height: Grade 1: 20–25% reduction; Grade 2: 25–40% reduction; Grade 3:
>40% reduction [40].
4.3. Biochemical Data
Blood samples were obtained by antecubital venipuncture between 8 a.m. and 11 a.m. after an
overnight fast and a 10 min rest. The first 4–5 mL of blood were not used. Blood was collected in
refrigerated vacutainers containing an anticoagulant mixture provided by Booehringer-Mannheim,
immediately placed on ice, and centrifuged, within a few minutes, at 2000× g for 20 min at 4 ◦C,
and the plasma was frozen at −80 ◦C until assayed. Osteocalcin (BGP) was performed using an
immunoenzymatic assay (Pantec, Turin, Italy). Serum levels of C-telopeptide of type I collagen
(CTx) was assessed using the Elecys 2010 Immunoassay System (Roche, Basel, Switzerland). Serum
calcium, serum phosphorus, and urinary creatinine were measured by automated routine procedures.
Parathyroid hormone (PTH) and 25-hydroxyvitamin D3 were measured using high-performance
liquid chromatography (Bio-Rad Laboratories S.r.l., Segrate, Milan, Italy). Vitamin D deficiency was
defined as plasma levels of 25(OH)D3 <20 ng/mL, insufficiency between 20 and 30 ng/m, and normal
>30 ng/mL. The intra- and inter-assay CV were <10% for both tests. The intra- and inter-assay CV
were <10% for both tests.
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4.4. Statistical Analysis
Statistical analyses were performed using Statistica 8 (Statsoft, Inc., Tulsa, OK, USA). Values
are expressed as mean SD or percentage. Comparisons between groups were performed by with a
Student’s t-test. The percentage of each variable was compared between groups by Fisher’s exact test.
A chi-squared test (χ2) with Yates correction was conducted to assess the individual association between
independent variables and the presence of insufficiency 25(OH)D3. Multivariate logistic regression
analysis was used to adjust for confounders. Values of p <0.05 were considered statistically significant.
5. Conclusions
In conclusion, our data showed a high prevalence of VFs in HIV-infected patients and highlight
the role of insufficiency of vitamin D3 in increasing the risk of VFs.
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